Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MariMed Inc. (MRMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly updates, and annual reports filed with the U.S. Securities and Exchange Commission. As a multi-state cannabis operator and cannabis consumer packaged goods company, MariMed uses these filings to report on its financial condition, operating performance, and material events.
Investors can review documents such as Form 8-K current reports, where MariMed furnishes press releases announcing quarterly results and other significant developments. These filings typically reference revenue, gross margin, net income or loss, and non-GAAP measures like Adjusted EBITDA and non-GAAP gross margin, along with management’s discussion of how these metrics are used to evaluate the business.
Through its periodic reports, MariMed also describes risks, uncertainties, and factors that could affect future performance, including changes in customer spending, regulatory approvals, and integration of acquired operations. Forward-looking statements in these filings are accompanied by cautionary language directing readers to additional risk discussions in the company’s reports.
On Stock Titan, each new MariMed filing is captured from the SEC’s EDGAR system and paired with AI-powered summaries that highlight key points, such as updates to financial results, explanations of non-GAAP metrics, and descriptions of material events. Users can quickly scan these summaries, then open the full filing for deeper review. This page also helps track items like insider and executive-related disclosures when they are reported on SEC forms, giving a structured view of MariMed’s regulatory reporting history.
Ryan Crandall, Chief Commercial Officer of MariMed, Inc. (MRMD), reported equity changes on 09/15/2025. On that date 62,901 restricted stock units (RSUs) vested and are convertible one-for-one into common shares. The issuer withheld 18,462 shares to satisfy tax withholding related to the RSU vesting. Following these transactions the reporting person is shown as beneficially owning 727,667 shares of common stock. The RSUs were originally granted on May 9, 2025, and the remaining portion of that award is scheduled to vest on December 15, 2025 under the award agreement.